ATE218341T1 - Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitor - Google Patents
Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitorInfo
- Publication number
- ATE218341T1 ATE218341T1 AT96932985T AT96932985T ATE218341T1 AT E218341 T1 ATE218341 T1 AT E218341T1 AT 96932985 T AT96932985 T AT 96932985T AT 96932985 T AT96932985 T AT 96932985T AT E218341 T1 ATE218341 T1 AT E218341T1
- Authority
- AT
- Austria
- Prior art keywords
- amadoric
- inhibitor
- post
- end products
- intermediate compounds
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US362895P | 1995-09-12 | 1995-09-12 | |
PCT/US1996/014544 WO1997009981A1 (en) | 1995-09-12 | 1996-09-11 | Advanced glycation end-product intermediaries and post-amadori inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE218341T1 true ATE218341T1 (de) | 2002-06-15 |
Family
ID=21706786
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01124700T ATE240103T1 (de) | 1995-09-12 | 1996-09-11 | Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori |
AT96932985T ATE218341T1 (de) | 1995-09-12 | 1996-09-11 | Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01124700T ATE240103T1 (de) | 1995-09-12 | 1996-09-11 | Intermediaires des produits definitifs de glycosylation avancee et inhibition des produits age post-amadori |
Country Status (11)
Country | Link |
---|---|
US (4) | US5744451A (de) |
EP (1) | EP0871443B1 (de) |
JP (2) | JPH11512432A (de) |
AT (2) | ATE240103T1 (de) |
AU (1) | AU717485B2 (de) |
CA (1) | CA2231772C (de) |
DE (2) | DE69621645T2 (de) |
DK (1) | DK0871443T3 (de) |
ES (2) | ES2177804T3 (de) |
PT (2) | PT871443E (de) |
WO (1) | WO1997009981A1 (de) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6740668B1 (en) | 1995-08-28 | 2004-05-25 | Kansas University Medical Center | Methods for inhibiting diabetic complications |
US6228858B1 (en) * | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US6716858B1 (en) | 1995-08-28 | 2004-04-06 | Kansas University Medical Center | Methods for inhibiting diabetic complications |
US5744451A (en) * | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
US6750209B1 (en) * | 1995-09-12 | 2004-06-15 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US6730686B1 (en) | 1995-09-12 | 2004-05-04 | Kansas University Medical Center | Methods for inhibiting oxidative modification of proteins |
US6436969B1 (en) * | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
US20030013746A1 (en) * | 1996-09-10 | 2003-01-16 | University Of Kansas Medical Center. | Advanced glycation end-product intermediaries and post-amadori inhibition |
US7071298B2 (en) | 1997-02-05 | 2006-07-04 | Fox Chase Cancer Center | Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins |
AU6518598A (en) * | 1997-03-28 | 1998-10-22 | Otsuka Pharmaceutical Co., Ltd. | Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b6 |
US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
WO1999007419A1 (en) * | 1997-08-07 | 1999-02-18 | Ajay Gupta | Dialysis solutions containing water soluble vitamins and nutrients |
US7704944B2 (en) * | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US7220717B2 (en) * | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
ATE295177T1 (de) * | 1998-03-16 | 2005-05-15 | Cytovia Inc | Dipeptid kaspase inhibitoren und deren verwendung |
KR100928878B1 (ko) | 1998-03-19 | 2009-11-30 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제의 억제제 |
EP2070535B1 (de) | 1998-08-24 | 2015-07-08 | Kurokawa, Kiyoshi | Wirkstoffe zur Minderung von Carbonylstress und Peritonealdialysaten |
US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
WO2000021516A2 (en) * | 1998-10-14 | 2000-04-20 | Kansas University Medical Center Research Institute, Inc. | Methods for inhibiting diabetic complications |
DE69908630T2 (de) * | 1998-10-22 | 2004-04-29 | University Of South Carolina | Verfahren zur hemmung von diabetischen komplikationen |
EP1126856A4 (de) * | 1998-10-28 | 2008-05-14 | Fox Chase Cancer Ct | Verbindungen und ihre therapeutische verwendung in diabetischen komplikationen |
US6121300A (en) * | 1998-11-10 | 2000-09-19 | Wagle; Dilip R. | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
WO2000051998A1 (en) * | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
WO2000051987A2 (en) | 1999-03-05 | 2000-09-08 | Kansas University Medical Center | Inhibitors of advanced, post-amadori glycosylation reactions |
DE60030097T2 (de) | 1999-03-16 | 2007-03-08 | Cytovia, Inc., San Diego | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
EP1165079A2 (de) * | 1999-04-06 | 2002-01-02 | Kansas University Medical Center | Verbesserte dialyse lösungen und verfahren |
BR0009610A (pt) | 1999-04-09 | 2002-02-13 | Cytovia Inc | Inibidores de caspase e uso dos mesmos |
US20020077276A1 (en) * | 1999-04-27 | 2002-06-20 | Fredeking Terry M. | Compositions and methods for treating hemorrhagic virus infections and other disorders |
EP1196171A2 (de) * | 1999-07-13 | 2002-04-17 | Medicure Inc. | Verwendung der pyridoxin-derivaten zur behandlung von diabetes und komplikationen davon |
EP1212295B1 (de) | 1999-08-27 | 2008-10-01 | Cytovia, Inc. | Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
DK1257292T3 (da) * | 2000-02-21 | 2011-07-18 | Merck Serono Sa | Anvendelse af IL-18-inhibitorer |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
WO2002022622A2 (en) | 2000-09-13 | 2002-03-21 | Georgetown University | Synthesis of 2-hydroxymethylglutamic acid and congeners thereof |
US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
WO2002039994A2 (en) | 2000-11-20 | 2002-05-23 | University Of Kansas Medical Center | Methods for the treatment and prevention of urinary stone disease |
DE60130030T2 (de) * | 2000-12-29 | 2008-04-30 | Alteon Inc. | Verfahren zur behandlung von glaukom |
DE10134568C2 (de) * | 2001-07-16 | 2003-07-24 | Inst Chemo Biosensorik | Verfahren zur quantitativen Bestimmung von alpha-Oxoaldehyd |
AU2003268292A1 (en) * | 2002-08-30 | 2004-03-19 | Biostratum, Inc. | Inhibitors of post-amadori advanced glycation end products |
US20050014799A1 (en) * | 2003-06-20 | 2005-01-20 | Biostratum, Inc. | Pyridoxamine for the treatment of diabetic kidney disease |
US20090082407A1 (en) * | 2004-06-18 | 2009-03-26 | Biostratum, Inc. | Pyridoxamine for the Treatment of Diabetic Kidney Disease |
JPWO2005018649A1 (ja) * | 2003-08-25 | 2007-11-01 | 財団法人名古屋産業科学研究所 | 最終糖化産物生成抑制剤 |
US20050192348A1 (en) * | 2003-09-25 | 2005-09-01 | David Bar-Or | Methods and products which utilize N-acyl-L-aspartic acid |
US7214799B2 (en) * | 2004-02-09 | 2007-05-08 | Biostratum, Inc. | Methods for the synthesis of pyridoxamine |
AU2005247409B2 (en) | 2004-05-15 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Treating seizures using ICE inhibitors |
EP1778221A2 (de) | 2004-05-27 | 2007-05-02 | Vertex Pharmaceuticals Incorporated | Ice-hemmer zur behandlung von autoinflammatorischen erkrankungen |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20060035890A1 (en) * | 2004-08-10 | 2006-02-16 | Amit Banerjee | Compounds and methods for the treatment of ubiquitin conjugating disorders |
US20080004320A1 (en) * | 2004-09-06 | 2008-01-03 | Kowa Co., Ltd. | Remedy for Glomerular Disease |
DE102005020976A1 (de) * | 2005-04-29 | 2006-11-02 | WÖRWAG PHARMA GmbH & Co. KG | Prophylaxe und Behandlung von Erkrankungen |
AU2006250547A1 (en) * | 2005-05-24 | 2006-11-30 | Tokai University Educational System | Peritoneal membrane protecting agent |
US8053449B2 (en) * | 2005-10-05 | 2011-11-08 | Cell Viable Corporation | Method for inhibiting AGE complex formation |
WO2008013660A2 (en) * | 2006-07-07 | 2008-01-31 | Biostratum, Inc. | Inhibitors of advanced glycation end products |
MY173496A (en) | 2010-02-10 | 2020-01-29 | Oryza Oil & Fat Chemical Co Ltd | Age production inhibitor |
EP2635906A4 (de) | 2010-11-05 | 2014-04-02 | Univ Brandeis | Ice-hemmende verbindungen und ihre verwendungen |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
CN103924249A (zh) * | 2013-01-11 | 2014-07-16 | 南京工业大学 | 一种席夫碱吡啶类碳钢酸洗缓蚀剂及其应用 |
BR112015026122A8 (pt) | 2013-04-18 | 2020-01-21 | Armo Biosciences Inc | agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
US10010588B2 (en) | 2013-08-30 | 2018-07-03 | Armo Biosciences, Inc. | Methods of using pegylated interleukin-10 for treating hyperlipidemia |
JP6148127B2 (ja) * | 2013-09-09 | 2017-06-14 | 株式会社パーマケム・アジア | ピリドキサール・アミノグアニジン誘導体またはそれらの塩、及び、その製造方法 |
US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
EP3187185A4 (de) * | 2014-08-29 | 2018-04-11 | Project PM Co., Ltd. | Pharmazeutische zusammensetzung aus der kombination einer pyridoxaminverbindung und einer thiaminverbindung |
WO2016060996A2 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
WO2016064817A1 (en) | 2014-10-22 | 2016-04-28 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
AU2016268403A1 (en) | 2015-05-28 | 2017-12-07 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
EP3341012A4 (de) | 2015-08-25 | 2019-03-20 | Armo Biosciences, Inc. | Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden |
JP6105111B1 (ja) | 2016-03-02 | 2017-03-29 | 国立大学法人東北大学 | 自閉スペクトラム症改善用組成物 |
JP2022542518A (ja) | 2019-08-01 | 2022-10-04 | プラエテゴ インコーポレイテッド | 終末糖化産物の抑制剤 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR4673M (de) | 1965-05-19 | 1966-12-19 | ||
FR7238M (de) | 1968-03-27 | 1969-09-01 | ||
CH607773A5 (en) | 1974-12-24 | 1978-10-31 | Steigerwald Arzneimittelwerk | Process for the preparation of novel pyridoxine derivatives |
DE2461742C2 (de) | 1974-12-28 | 1983-01-27 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt | Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
FR2349330A1 (fr) | 1976-04-29 | 1977-11-25 | Savini Emile | Composition destinee au traitement des hyperlipidemies |
US4983604A (en) * | 1987-11-13 | 1991-01-08 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
US5175192A (en) * | 1984-03-19 | 1992-12-29 | The Rockefeller University | Inhibitors of the advanced glycosylation of proteins and methods of use therefor |
US4758583A (en) * | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
US5358960A (en) * | 1984-03-19 | 1994-10-25 | The Rockefeller University | Method for inhibiting advanced glycosylation of proteins using aminosubstituted imidazoles |
US5100919A (en) * | 1984-03-19 | 1992-03-31 | The Rockefeller University | Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein |
US5137916A (en) * | 1985-11-14 | 1992-08-11 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
US5318982A (en) * | 1984-03-19 | 1994-06-07 | The Rockefeller University | Inhibition of the advanced glycosylation of proteins using substituted-1,2,4-triazoles |
US5262152A (en) * | 1984-03-19 | 1993-11-16 | The Rockefeller University | Amidrazones and derivatives thereof |
US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
US5140048A (en) * | 1984-03-19 | 1992-08-18 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
US5272176A (en) * | 1984-03-19 | 1993-12-21 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
US4665192A (en) * | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
US5130324A (en) * | 1984-03-19 | 1992-07-14 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5258381A (en) * | 1984-03-19 | 1993-11-02 | The Rockefeller University | 2-substituted-2-imidazolines |
US4908446A (en) * | 1985-11-14 | 1990-03-13 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
US5221683A (en) * | 1984-03-19 | 1993-06-22 | The Rockefeller University | Diaminopyridine compounds and methods of use |
US5272165A (en) * | 1984-03-19 | 1993-12-21 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5218001A (en) * | 1984-03-19 | 1993-06-08 | The Rockefeller University | Inhibitors of the advanced glycosylation of proteins and methods of use therefor |
US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
DE3705549A1 (de) | 1987-02-18 | 1988-09-01 | Ulrich Speck | Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose |
US5288716A (en) * | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US5017696A (en) * | 1987-09-17 | 1991-05-21 | The Rockefeller University | Advanced glycosylation end products and associated methods |
US5010175A (en) * | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5242593A (en) * | 1988-12-09 | 1993-09-07 | Oberkofler Joerg | Method for reducing the build-up of slime and/or film in water circulation systems |
ES2078509T3 (es) | 1990-02-19 | 1995-12-16 | Senju Pharma Co | Composiciones inhibidoras de la reaccion de maillard. |
AU8449591A (en) * | 1990-08-01 | 1992-03-02 | Rockefeller University, The | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
CA2055990A1 (en) | 1990-11-22 | 1992-05-23 | David G. Schena | Phospholipid-vitamin derivatives and methods for preparation thereof |
EP0668870A1 (de) * | 1991-06-14 | 1995-08-30 | Chiron Corporation | Inhibitoren der picornavirus-protease |
US5552400A (en) * | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US6162828A (en) * | 1995-03-31 | 2000-12-19 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
US6228858B1 (en) | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5744451A (en) * | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
-
1996
- 1996-08-13 US US08/700,716 patent/US5744451A/en not_active Expired - Lifetime
- 1996-09-10 US US08/711,555 patent/US5985857A/en not_active Expired - Lifetime
- 1996-09-11 DE DE69621645T patent/DE69621645T2/de not_active Expired - Lifetime
- 1996-09-11 PT PT96932985T patent/PT871443E/pt unknown
- 1996-09-11 JP JP9512053A patent/JPH11512432A/ja not_active Ceased
- 1996-09-11 AT AT01124700T patent/ATE240103T1/de active
- 1996-09-11 DK DK96932985T patent/DK0871443T3/da active
- 1996-09-11 WO PCT/US1996/014544 patent/WO1997009981A1/en active IP Right Grant
- 1996-09-11 ES ES96932985T patent/ES2177804T3/es not_active Expired - Lifetime
- 1996-09-11 EP EP96932985A patent/EP0871443B1/de not_active Expired - Lifetime
- 1996-09-11 ES ES01124700T patent/ES2199913T3/es not_active Expired - Lifetime
- 1996-09-11 AT AT96932985T patent/ATE218341T1/de active
- 1996-09-11 CA CA2231772A patent/CA2231772C/en not_active Expired - Lifetime
- 1996-09-11 PT PT01124700T patent/PT1190713E/pt unknown
- 1996-09-11 AU AU71566/96A patent/AU717485B2/en not_active Expired
- 1996-09-11 DE DE69628214T patent/DE69628214T2/de not_active Expired - Lifetime
-
1998
- 1998-04-27 US US09/067,053 patent/US5932549A/en not_active Expired - Fee Related
-
1999
- 1999-05-28 US US09/322,569 patent/US6472400B1/en not_active Expired - Lifetime
-
2004
- 2004-11-18 JP JP2004334202A patent/JP3769003B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PT871443E (pt) | 2002-10-31 |
US6472400B1 (en) | 2002-10-29 |
PT1190713E (pt) | 2003-09-30 |
DE69621645T2 (de) | 2002-09-19 |
CA2231772C (en) | 2011-05-31 |
CA2231772A1 (en) | 1997-03-20 |
ES2199913T3 (es) | 2004-03-01 |
JP3769003B2 (ja) | 2006-04-19 |
DE69628214D1 (de) | 2003-06-18 |
DE69628214T2 (de) | 2003-11-27 |
AU717485B2 (en) | 2000-03-30 |
US5744451A (en) | 1998-04-28 |
ATE240103T1 (de) | 2003-05-15 |
DK0871443T3 (da) | 2002-07-01 |
AU7156696A (en) | 1997-04-01 |
WO1997009981A1 (en) | 1997-03-20 |
JPH11512432A (ja) | 1999-10-26 |
US5932549A (en) | 1999-08-03 |
JP2005170935A (ja) | 2005-06-30 |
EP0871443A1 (de) | 1998-10-21 |
ES2177804T3 (es) | 2002-12-16 |
EP0871443B1 (de) | 2002-06-05 |
US5985857A (en) | 1999-11-16 |
DE69621645D1 (de) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE218341T1 (de) | Zwischenverbindungen von fortgeschrittenen glykosylierung-endprodukten und post-amadorische inhibitor | |
NZ240230A (en) | Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof | |
HUP0001539A2 (hu) | 2-(1-Imino-etil-amino)-etil-homocisztein, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmények | |
DE69635458D1 (de) | Inhibitoren des interleukin-1-beta konvertierenden enzyms | |
HUP0100156A2 (hu) | Foszfolipáz-A2 inhibitor hatású indolszármazékok és alkalmazásuk gyógyászati készítmények előállítására | |
FI964473A (fi) | Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II) | |
EA199900448A1 (ru) | Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos | |
ATE230749T1 (de) | Glucocorticoid selektive entzündungshemmende mittel | |
IT1221079B (it) | Derivati di anilina terapeuticamente attivi,procedimento per la loro preparazione e composizioni farmaceutiche che il contengono | |
HUP0000288A3 (en) | Azetidinone derivatives as inhibitors of the enzymatic activity of psa, intermediates, process for their preparation and pharmaceutical compositions thereof | |
ES2173887T3 (es) | Nuevos usos farmaceuticos de las enzimas de krill. | |
HUP0000664A3 (en) | Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use of them for producing pharmaceutical compositions | |
EE9900112A (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
WO1999040061A3 (en) | Novel dihydroxyhexanoic acid derivatives | |
MX9403088A (es) | Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso. | |
IT1276162B1 (it) | Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche | |
DE69819539D1 (de) | Antithrombotische mittel | |
IT1196377B (it) | Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche | |
HUP0202988A3 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
EP1027051A4 (de) | Antithrombotische mittel | |
ITMI950132A1 (it) | Derivati tiolici ad attivita' inibitrice delle metallopeptidasi | |
FI972129A (fi) | 6-metoksi-1H-bentsotriatsoli-5-karboksamidijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä lääkekoostumuksia | |
DE69824410D1 (en) | Antithrombosemittel | |
NZ232153A (en) | Carboxylic acid derivatives, preparation, and pharmaceutical compositions | |
IT1213033B (it) | Esteri di n-alchil-nortropine eloro derivati ammonioquaternari aventi attivita'anti-broncospastica, procedimento per la loro preparazione e composizioni farmaceutiche che licontengono. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0871443 Country of ref document: EP |